Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA’s New ‘Super Office’ Attacks Pharmaceutical Quality Risks

This article was originally published in The Gold Sheet

Executive Summary

Launched this month, CDER’s OPQ ‘Super Office’ blends the agency’s CMC review programs for new and generic drugs together, and focuses them on significant risks like the difficulty of release-testing modified-release drugs.

You may also be interested in...

FDA’s OPQ Chief Tells Generic Drug Makers Its Time To Up Their Quality Game

The head of US FDA’s drug quality office comments on quality-related topics at the GRx-Biosims meeting; sheds more light on facility rating system plan.

FDA Generics Research Forges Ahead After Agency’s Bupropion Mea Culpa

In an unusual essay in the New England Journal of Medicine, CDER Director Janet Woodcock acknowledges that “the conservative approach did not provide the right conclusion regarding therapeutic equivalence in a timely manner.”

Consortium Costs Debated As BARDA, Industry Discuss Plans For Next Pandemic Response

BARDA’s consortium approach scrutinized as industry recovers from US Defense Production Act rated orders. Questions of sustainment fees, interruptible commercial activities explored during BioMaC Industry Day call as agency emphasizes need for proven capacity.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts